How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

366 results for

Intraocular Carbonic Anhydrase Inhibitor

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Dorzolamide-timolol Drops With Injections to Treat AMD,RVO or DME.

Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Growth Substances Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Study Start Date : October 1, 2014 Actual Primary Completion Date : July 10, 2017 Actual Study Completion Date : December 1, 2017 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Dorzolamide-timolol On enrollment, eligible patients will have visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan and will then receive the same intravitreal

2015 Clinical Trials

82. Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

of oral prednisone at baseline (M01 study visit) dose stability requirement for past 4 weeks does not apply); Systemic immunosuppressive drug therapy that has not been stable for at least 4 weeks (note: use of systemic methotrexate is acceptable as long as regimen has been stable for at least 4 weeks); Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline; Known allergy or hypersensitivity to any component of the study drugs; For women of childbearing potential (...) variable with a limited duration. Persistent macular edema is a common occurrence and often requires repeated intravitreal injections of corticosteroids, which expose eyes to a significant risk of increased intraocular pressure ocular and cataract development. The often refractory nature of uveitic ME and its impact on visual function underscores the need to identify effective alternative medical therapeutic options. Recent pilot studies have shown intravitreal methotrexate (MTX) and intravitreal

2015 Clinical Trials

83. Laser Peripheral Iridotomy Plus Laser Peripheral Iridoplasty for Primary Angle Closure

worse visual acuity will be selected. Only one eye per patient is eligible for the study. Drug washout: Eligible patients who are already on anti-glaucoma medications are required to have drug washout before being randomized. Various medications have different washout periods: Prostaglandin analogues 4 weeks, Beta blockers 3 weeks, Adrenergic agonist 2 weeks, Cholinergic agonist 5 days, Carbonic Anhydrase Inhibitors 5 days. Patients whose IOP>30 mm Hg during this washout period will be stopped from (...) after LPIP procedure. Drug: Proparacaine 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered Outcome Measures Go to Primary Outcome Measures : Progression rate determined by number of patients who progress after laser treatment for each group. [ Time Frame: 3 years ] PAC progression defined as presence of any of the following: Acute angle closure crisis Intraocular (IOP) was 8mmHg higher

2015 Clinical Trials

84. PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial

of infectious uveitis, or of scleritis, keratitis, or infectious endophthalmitis in either eye; History of central serous retinopathy in either eye; For women of childbearing potential: pregnancy, breastfeeding, or a positive pregnancy test; unwilling to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for duration of trial; Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline; Oral prednisone dose > 10 mg per day (...) , regardless of the presence of cysts, as assessed by study ophthalmologist; Best corrected visual acuity (BCVA) 5/200 or better; Baseline intraocular pressure > 5 mm Hg and ≤ 21 mm Hg (current use of 3 or fewer intraocular pressure-lowering medications and/or prior glaucoma surgery are acceptable); Baseline fluorescein angiogram that is gradable for leakage in the central subfield Pupillary dilation sufficient to allow OCT testing. Exclusion Criteria: Patient level exclusion criteria: -History

2015 Clinical Trials

85. Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

such as retinal degeneration, diabetic retinopathy, or retinal detachment; Best-corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to approximately 0.60 logMAR, 20/80 Snellen, or 0.25 decimal); Other ocular pathology (including severe dry eye) that may preclude the administration of α-adrenergic agonist and/or topical carbonic anhydrase inhibitor (CAI); Intraocular surgery within the past 6 months; Ocular laser surgery within the past 3 months; Any abnormality preventing reliable (...) Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors

2015 Clinical Trials

86. Early Aqueous Suppressant Therapy on Hypertensive Phase Following Glaucoma Drainage Device Procedure: A Randomized Prospective Trial. (Abstract)

Early Aqueous Suppressant Therapy on Hypertensive Phase Following Glaucoma Drainage Device Procedure: A Randomized Prospective Trial. To prospectively evaluate the effect of early aqueous suppression (therapy) on hypertensive phase (HP) and intraocular pressure (IOP) control after implantation of silicone Ahmed glaucoma valve (AGV).Patients who underwent AGV implantation were randomized to initiate therapy (including β-blockers, α-agonists, or carbonic anhydrase inhibitors) when postoperative

2014 Journal of glaucoma Controlled trial quality: uncertain

87. Glaucoma in pregnancy. (Abstract)

on animal studies. Other glaucoma medications (beta blockers, carbonic anhydrase inhibitors, parasympathomimetics, and prostaglandin analogues) are classified as category C medications with uncertain safety from the lack of human studies and reported adverse effects in animal studies.The treatment of glaucoma during pregnancy and lactation requires careful consideration and understanding of disease status, stage of pregnancy, FDA classification and guidelines, and potential benefits and limitations (...) , the natural course of intraocular pressure during pregnancy, and a discussion of various therapeutic modalities during pregnancy and lactation.The risks of glaucoma medications during pregnancy are not well established for the human fetus or infant and are often inferred from animal studies. Some guidelines have been provided by the US Food and Drug Administration (FDA) about medication safety during pregnancy. Currently, brimonidine is classified as a category B medication with presumed safety based

2014 Current Opinion in Ophthalmology

88. Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration

in the study eye, uncontrolled IOP, or use of two or more agents to control IOP (acetazolamide, beta blocker, alpha-1-agonist, antprostaglandins, carbonic anhydrase inhibitors). Cataract of sufficient severity likely to necessitate surgical extraction within 1 year. History of retinal detachment repair in the study eye. History of malignancy (with the exception of successfully treated [excised] basal cell carcinoma [skin cancer] or successfully treated squamous cell carcinoma of the skin). History (...) -retinal barrier. Glaucoma. Uveitis or other intraocular inflammatory disease. Significant lens opacities or other media opacity. Ocular lens removal within previous 3 months. Ocular surgery in the study eye in the previous 3 months If female, pregnancy or lactation. Any other medical condition, which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromises patient safety, or interferes with the interpretation of the study results. Contacts

2014 Clinical Trials

89. Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis

and testing of the retina. The study eye has undergone intraocular surgery within six months prior to enrollment. The study eye is receiving topical carbonic anhydrase inhibitor, or has received topical carbonic anhydrase inhibitors in the past three months. STUDY EYE SELECTION CRITERIA: If both eyes of a participant meet the study eye eligibility criteria, the choice of study eye will be determined as follows: The eye with the worse visual acuity will be selected as the study eye. If both eyes have (...) is currently taking, or has taken in the last three months, a systemic carbonic anhydrase inhibitor prior to enrollment/baseline 1 testing. Participant has any condition that significantly increases risk of systemic corticosteroids or systemic steroid-sparing immuno-modulatory agents, such as HIV, syphilis, tuberculosis, hepatitis B, hepatitis C, or diabetes mellitus (DM). Participant has an underlying serious illness that impairs regular follow-up during the study. Participant has had diagnosis

2014 Clinical Trials

90. Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients

Exclusion Criteria: history of ocular trauma intraocular surgery (except for cataract surgery) eye disease associated with hemodynamic disturbances (except glaucoma) systemic diseases with ocular involvement like diabetes contra-indications to the use of topical beta-blockers or carbonic anhydrase inhibitors Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information (...) as to why these RI values are associated with progression, the clinical question arises as to whether these cutpoints can be modulated by topical glaucoma therapy. As some medications such as carbonic anhydrase inhibitors have been found to have a positive effect in disease progression in what appears to be a non-IOP related effect, we considered the hypothesis that these drugs could have a positive impact on the ocular's microcirculation vasoactive response, potentially enabling to keep a steady MFV

2014 Clinical Trials

91. Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa

(diaphragm, condom) with spermicide, or surgical sterilization (hysterectomy or tubal ligation). EXCLUSION CRITERIA: A participant is not eligible if any of the following exclusion criteria are present. Participant is actively receiving study therapy in another investigational study. Participant is started on (or changed dosage of) topical or systemic carbonic anhydrase inhibitor (CAI) treatment in the 3 months prior to enrollment. Participant is actively receiving systemic steroids or has received (...) cell death, including that of associated cystoid macular edema (CME), is not completely understood. Inflammatory processes involving the activation of resident immune cells of the retina called microglia have been hypothesized to contribute. Minocycline inhibits the activation of microglia, decreasing the production of inflammatory factors implicated in RP progression. The objective of this study is to investigate the safety and possible efficacy of oral minocycline in participants with CME and RP

2014 Clinical Trials

92. 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

or topical carbonic anhydrase inhibitor; Intraocular surgery within the past 6 months prior to the Screening Visit; Ocular laser surgery within the past 3 months prior to the Screening Visit; Any abnormality preventing reliable applanation tonometry; Any other conditions including severe illness which would make the subject, in the opinion of the Investigator, unsuitable for the study; History of hepatic or renal disease that would preclude the safe administration of a carbonic anhydrase inhibitor (CAI (...) First Posted: December 29, 2015 Last Update Posted: December 29, 2015 Last Verified: November 2015 Keywords provided by Alcon Research: Glaucoma Ocular Hypertension OAG POAG OHT Additional relevant MeSH terms: Layout table for MeSH terms Hypertension Glaucoma Glaucoma, Open-Angle Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Pharmaceutical Solutions Ophthalmic Solutions Travoprost Brinzolamide Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors

2014 Clinical Trials

93. Comparison of Combigan BID Versus Simbrinza TID

Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug. Condition or disease Intervention/treatment Phase Glaucoma Ocular Hypertension Drug: Combigan Two Times Daily (BID) Drug: Simbrinza Three Times Daily (TID) Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 43 participants Allocation: Randomized

2014 Clinical Trials

94. Topical brinzolamide (Azopt) versus placebo in the treatment of infantile nystagmus syndrome (INS). (Abstract)

Topical brinzolamide (Azopt) versus placebo in the treatment of infantile nystagmus syndrome (INS). To test the hypothesis that the topical carbonic anhydrase inhibitor brinzolamide (Azopt) has beneficial effects versus placebo on measures of nystagmus and visual acuity in adult subjects with infantile nystagmus syndrome (INS).Prospective, cross-over, double masked clinical trial.Single centre.Five subjects ≥18 years old with typical INS and best-binocular visual acuity in their primary (...) optotype visual acuity, using the ETDRS protocol analysed individually and as a group before and after Azopt and placebo.Versus placebo and baseline measures, topical Azopt significantly improved; INS waveform characteristics in the primary position null zone, group mean values of the nystagmus acuity function across gaze (p<0.01) and group mean ETDRS binocular letter visual acuity (p<0.05). There was a predictable decrease in intraocular pressure (IOP) without any systemic or ocular adverse

2014 British Journal of Ophthalmology Controlled trial quality: uncertain

95. The Effect of Long-term Antiglaucomatous Drug Administration on Central Corneal Thickness. (Abstract)

).We recommend regular measurements before and during therapy with prostaglandin monotherapy and a combined therapy with prostaglandins, carbonic anhydrase inhibitors, and β-blockers. Follow-up intraocular pressure measurements may be underestimated for eyes treated with the aforementioned treatment regimens if central corneal thickness is not measured on a regular basis. (...) The Effect of Long-term Antiglaucomatous Drug Administration on Central Corneal Thickness. To evaluate rates of changes per year of central corneal thickness after antiglaucomatous drug administration with β-blockers, prostaglandin analogs, and carbonic anhydrase inhibitors monotherapy and combined topical antiglaucomatous therapy, in a cohort of patients with ocular hypertension, glaucoma suspects, and patients with perimetric glaucoma as compared with normal controls.This retrospective single

2014 Journal of Glaucoma

96. Glaucoma, Primary Open Angle (Overview)

, dorzolamide/timolol) Alpha agonist/carbonic anhydrase inhibitor (eg, brimonidine/brinzolamide) Laser therapy Laser can be used as primary or adjunctive treatment. It is indicated in cases of noncompliance with medications or if the patient is on maximum tolerated medical therapy and needs further intraocular pressure reduction. The following are laser options that may be used for primary open-angle glaucoma: Argon laser trabeculoplasty (ALT) Selective laser trabeculoplasty (SLT) Micropulse diode laser (...) , brimonidine, apraclonidine) Less-selective sympathomimetics (eg, dipivefrin, epinephrine) Carbonic anhydrase inhibitors (eg, dorzolamide, brinzolamide, acetazolamide, methazolamide) Prostaglandin analogs (eg, latanoprost, bimatoprost, travoprost, tafluprost, latanoprostene bunod) Miotic agents (eg, pilocarpine) Hyperosmotic agents (eg, isosorbide dinitrate, mannitol, glycerin) Beta-blocker/alpha agonist combination (eg, brimonidine/timolol) Beta-blocker/carbonic anhydrase inhibitor combination (eg

2014 eMedicine.com

97. Sturge-Weber Syndrome (Overview)

is preferable in SWS. The chance of achieving seizure control with medical therapy in patients with SWS varies. Glaucoma medications The goal of treatment is control of IOP to prevent optic nerve injury. This can be achieved with the following agents: Beta-antagonist eye drops - Decrease the production of aqueous fluid Carbonic anhydrase inhibitors - Also decrease production of aqueous fluid Adrenergic eye drops and miotic eye drops - Promote drainage of aqueous fluid Dye laser photocoagulation Treatment (...) the presence of infantile glaucoma include the following: Corneal diameter of more than 12 mm during the first year of life Corneal edema Tears in the Descemet membrane (Haab striae) Unilateral or bilateral myopic shift Optic nerve cupping greater than 0.3 Any cup asymmetry associated with intraocular pressure (IOP) above the high teens Optic nerve damage - Resulting in myopia, anisometropia, amblyopia, strabismus, and visual field defects Diagnosis In young patients, examination under anesthesia or deep

2014 eMedicine.com

98. Sturge-Weber Syndrome (Overview)

is preferable in SWS. The chance of achieving seizure control with medical therapy in patients with SWS varies. Glaucoma medications The goal of treatment is control of IOP to prevent optic nerve injury. This can be achieved with the following agents: Beta-antagonist eye drops - Decrease the production of aqueous fluid Carbonic anhydrase inhibitors - Also decrease production of aqueous fluid Adrenergic eye drops and miotic eye drops - Promote drainage of aqueous fluid Dye laser photocoagulation Treatment (...) the presence of infantile glaucoma include the following: Corneal diameter of more than 12 mm during the first year of life Corneal edema Tears in the Descemet membrane (Haab striae) Unilateral or bilateral myopic shift Optic nerve cupping greater than 0.3 Any cup asymmetry associated with intraocular pressure (IOP) above the high teens Optic nerve damage - Resulting in myopia, anisometropia, amblyopia, strabismus, and visual field defects Diagnosis In young patients, examination under anesthesia or deep

2014 eMedicine.com

99. Glaucoma, Drainage Devices (Overview)

, dorzolamide/timolol) Alpha agonist/carbonic anhydrase inhibitor (eg, brimonidine/brinzolamide) Laser therapy Laser can be used as primary or adjunctive treatment. It is indicated in cases of noncompliance with medications or if the patient is on maximum tolerated medical therapy and needs further intraocular pressure reduction. The following are laser options that may be used for primary open-angle glaucoma: Argon laser trabeculoplasty (ALT) Selective laser trabeculoplasty (SLT) Micropulse diode laser (...) , brimonidine, apraclonidine) Less-selective sympathomimetics (eg, dipivefrin, epinephrine) Carbonic anhydrase inhibitors (eg, dorzolamide, brinzolamide, acetazolamide, methazolamide) Prostaglandin analogs (eg, latanoprost, bimatoprost, travoprost, tafluprost, latanoprostene bunod) Miotic agents (eg, pilocarpine) Hyperosmotic agents (eg, isosorbide dinitrate, mannitol, glycerin) Beta-blocker/alpha agonist combination (eg, brimonidine/timolol) Beta-blocker/carbonic anhydrase inhibitor combination (eg

2014 eMedicine.com

100. Glaucoma and Penetrating Keratoplasty (Overview)

Inflammation, graft rejection, retinal detachment, subconjunctival fibrosis Topical carbonic anhydrase inhibitors Induce permanent graft failure in eyes with borderline endothelial counts Prostaglandin analogues Uveitis, cystoid macular edema in aphakia and pseudophakia, and recurrent herpes simplex infection in patients with previous history of herpes Adrenergic agents Epithelial toxicity and cystoid macular edema in aphakia and pseudophakia Contributor Information and Disclosures Author Kristin Schmid (...) of the Procedure In 1969, Irvine and Kaufman reported the high incidence of increased intraocular pressure (IOP) following PKP. [ ] They reported a mean maximum pressure of 40 mm Hg in aphakic transplants and 50 mm Hg in combined transplants and cataract extraction in the immediate postoperative period. Since then, numerous authors have reported on the incidence and management of PKPG. Previous Next: Epidemiology Frequency The incidence of PKPG varies from 9-31% in the early postoperative period

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>